The LS CancerDiag research team, led by CSO Minttu Kansikas, Ph.D., recently published a peer-reviewed article in Cancer Research Communications (March 2023). The article provides results for the clinical validation of the DiagMMR test based
Introducing the newest LS CancerDiag Board Members: Patrik Dahlén and Tuomas Tenkanen We aim to improve and significantly increase the detection of Lynch syndrome in the population and create a new diagnostic standard with our
Lynch syndrome genetics and clinical implications The Gastroenterology journal (January 2023) features a review article by Professors Päivi Peltomäki, Minna Nyström, Jukka-Pekka Mecklin, and Toni T. Seppälä titled “Lynch Syndrome Genetics and Clinical Implications”. The
Professor Minna Nyström studies Lynch syndrome out of love for methods and genetics, with a dream to develop a test that benefits the world Minna Nyström is the chairman of the board of LS CancerDiag,
LS CancerDiag’s 5.4 million euro share issue was fully subscribed in just five days by 600 Finnish private investors. The company’s innovation can save millions of human lives by improving the diagnosis of Lynch syndrome,
LS CancerDiag has opened its next funding round in collaboration with Springvest, who provides opportunities to invest in promising unlisted growth companies. The company aims to raise €5.4M in capital to support the expansion into
LS CancerDiag has successfully passed through the auditing process to receive the certification according to the ISO 13485:2016 standard. This internationally agreed standard sets out the requirements for a quality management system specific to the
Business Finland, the government organization for innovation funding and trade, travel and investment promotion, has published a brochure on ‘World-class diagnostic innovations from Finland‘. The digital booklet showcases Finland’s strong capabilities in research, development &
Congratulations to Niklas for qualifying LS CancerDiag to the EIT Health Catapult semifinals! Introducing a unique competition and training programme that showcases biotech, medtech and digital health start-ups to leading experts and investors across Europe.
Last month LS CancerDiag was selected as one of the 11 female-led start-ups to the EIT Health Women Entrepreneurship Bootcamp. The Women Entrepreneurship Bootcamp connects high growth, women-led or co-led start-ups to an unparalleled network
Twitter feed is not available at the moment.
LS CancerDiag has launched a funding round in collaboration with Springvest.
The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.
